Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Clinical Study of HX301 Alone or in Combination with Temozolomide in Patients with High-Grade Glioma (Grade III and IV)

NCT06703255 is registered in ClinicalTrials.gov with Hangzhou Hanx Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT06703255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06703255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Clinical Study of HX301 Alone or in Combination with Temozolomide in Patients with High-Grade Glioma (Grade III and IV)
Lead sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 8, 2025
Completion date
December 31, 2028
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma